If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
58
results.
Updated on
01/09/2024 [06:45:00]
Results 50 to 58 of 58
Absstract of: US2024262917A1
The present invention is directed to human monoclonal antibodies that bind to Anaplastic Lymphoma Kinase (ALK).
Absstract of: WO2024160845A1
New PCT-application based on EP 23 154 047.7 Ludwig-Maximilians-Universität München, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt Vossius Ref.: AF3867 PCT S3 ABSTRACT The present invention relates to the recognition of CD86 as a marker of hematological cancer and thus relates to CD86 targeting agents for the treatment of such cancers, in particular, acute myeloid leukemia (AML), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). The invention in particular encompasses a lymphocyte recombinantly expressing a chimeric antigen T cell receptor (CAR) comprising an antigen binding domain that specifically binds CD86 for use in the treatment of such cancers, as well as also encompassing the CAR construct, i.e., comprising an antigen binding domain that specifically binds CD86.
Absstract of: US2024261259A1
Methods are provided for predicting the efficacy of midostaurin for the treatment of a cancer in an individual subject or a cohort of patients. The method comprises determining a phosphoproteomic and/or a proteomic signature within a sample obtained from the individual subject wherein the phosphoproteomic and/or proteomic signature provides a personalised prediction for the individual subject of the efficacy of midostaurin for treatment of cancer. This invention has utility in methods for treatment of a range of cancers including acute myeloid leukaemia (AML). Companion diagnostic kits and their use in dosage regimens for the treatment of cancer are also provided.
Absstract of: EP4410790A1
The present invention relates to an SOS1 inhibitor with a pyrido-fused-six-membered ring structure, a preparation method therefor, and use thereof. The SOS1 inhibitor has the structural formula shown in formula (I) and an inhibitory activity on SOS1, and can be used to treat head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.
Absstract of: WO2023052354A1
The present disclosure relates to the compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acceptable salts which are NPM1 inhibitors. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer.
Absstract of: EP4410377A2
Compounds for use in methods of treating haematological disorders, in particular diffuse large B-cell lymphoma (DLBCL), using a substituted indazole compound or a pharmaceutically acceptable salt thereof and a compound which inhibits BCL-2 kinases.
Absstract of: WO2024158001A1
The present invention provides a method for treating canine B cell lymphoma that has a superior effect as compared to existing methods. Provided is a method for treating canine B cell lymphoma wherein a monoclonal antibody for canine CD20 and a chemotherapeutic agent are administered in combination, either simultaneously or sequentially. The chemotherapeutic agent is one or more agents from among vincristine, cyclophosphamide, prednisolone, and doxorubicin, and is administered in combination with the monoclonal antibody for canine CD20, either simultaneously or sequentially.
Nº publicación: WO2024156672A1 02/08/2024
Applicant:
F HOFFMANN LA ROCHE AG [CH]
HOFFMANN LA ROCHE INC [US]
KLINIKUM DER UNIV MUENCHEN [DE]
F. HOFFMANN-LA ROCHE AG,
HOFFMANN-LA ROCHE INC,
KLINIKUM DER UNIVERSIT\u00C4T M\u00DCNCHEN
Absstract of: WO2024156672A1
The present invention generally relates to antibodies that bind to CSF1R and CD3, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease, in particular in the treatment of acute myeloid leukemia (AML).
BOPI
Electronic site
